These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 17368885

  • 21. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.
    Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarria P, Collini P, Gronchi A, Olmi P, Fossati-Bellani F, Casali PG.
    Cancer; 2003 Aug 01; 98(3):571-80. PubMed ID: 12879475
    [Abstract] [Full Text] [Related]

  • 22. Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: implications for patterns of disease recurrence and overall survival.
    Eaton BR, McDonald MW, Kim S, Marcus RB, Sutter AL, Chen Z, Esiashvili N.
    Cancer; 2013 Apr 15; 119(8):1578-85. PubMed ID: 23280478
    [Abstract] [Full Text] [Related]

  • 23. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
    Massimino M, Gandola L, Spreafico F, Luksch R, Collini P, Giangaspero F, Simonetti F, Casanova M, Cefalo G, Pignoli E, Ferrari A, Terenziani M, Podda M, Meazza C, Polastri D, Poggi G, Ravagnani F, Fossati-Bellani F.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1031-7. PubMed ID: 16343801
    [Abstract] [Full Text] [Related]

  • 24. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL, Smith LM, Ruymann FB, Qualman SJ, Donaldson SS, Rodeberg DA, Anderson JR, Crist WM, Link MP.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [Abstract] [Full Text] [Related]

  • 25. Possible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy.
    Matsubara H, Makimoto A, Higa T, Kawamoto H, Takayama J, Ohira M, Yokoyama R, Beppu Y, Takaue Y.
    Pediatr Hematol Oncol; 2003 Sep 15; 20(3):201-10. PubMed ID: 12637216
    [Abstract] [Full Text] [Related]

  • 26. Adult rhabdomyosarcoma: outcome following multimodality treatment.
    Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK, Garden AS, Benjamin RS.
    Cancer; 2002 Jul 15; 95(2):377-88. PubMed ID: 12124838
    [Abstract] [Full Text] [Related]

  • 27. Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.
    Casey DL, Wexler LH, Wolden SL.
    Int J Radiat Oncol Biol Phys; 2019 Apr 01; 103(5):1151-1157. PubMed ID: 30508617
    [Abstract] [Full Text] [Related]

  • 28. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.
    McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C, Bergeron C.
    Eur J Cancer; 2010 Jun 01; 46(9):1588-95. PubMed ID: 20338746
    [Abstract] [Full Text] [Related]

  • 29. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute.
    Timmermann B, Schuck A, Niggli F, Weiss M, Lomax AJ, Pedroni E, Coray A, Jermann M, Rutz HP, Goitein G.
    Int J Radiat Oncol Biol Phys; 2007 Feb 01; 67(2):497-504. PubMed ID: 17084557
    [Abstract] [Full Text] [Related]

  • 30. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma.
    McDonald MW, Esiashvili N, George BA, Katzenstein HM, Olson TA, Rapkin LB, Marcus RB.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):884-91. PubMed ID: 18455321
    [Abstract] [Full Text] [Related]

  • 31. [Localised rhabdomyosarcoma of the extremities in children and adolescents: results of the French experience].
    Diepold M, Rey A, Oberlin O, Boulay N, Bergeron C, Glorion C, Mary P, Terrier-Lacombe MJ, Helfre S, Habrand JL, Gentet JC, Defachelles AS, Thomas C, Brisse H, Pierron G, Orbach D.
    Bull Cancer; 2008 Nov 01; 95(11):1021-8. PubMed ID: 19036673
    [Abstract] [Full Text] [Related]

  • 32. Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV.
    Rodeberg D, Arndt C, Breneman J, Lyden E, Donaldson S, Paidas C, Andrassy R, Meyer W, Wiener E.
    J Pediatr Surg; 2005 Jan 01; 40(1):256-62. PubMed ID: 15868594
    [Abstract] [Full Text] [Related]

  • 33. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Arndt CA, Hawkins DS, Meyer WH, Sencer SF, Neglia JP, Anderson JR.
    Pediatr Blood Cancer; 2008 Jan 01; 50(1):33-6. PubMed ID: 17091486
    [Abstract] [Full Text] [Related]

  • 34. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Burke M, Anderson JR, Kao SC, Rodeberg D, Qualman SJ, Wolden SL, Meyer WH, Breitfeld PP, Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    J Clin Oncol; 2007 Nov 01; 25(31):4909-13. PubMed ID: 17971587
    [Abstract] [Full Text] [Related]

  • 35. Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group.
    Ferrari A, Casanova M, Bisogno G, Zanetti I, Cecchetto G, De Bernardi B, Riccardi R, Tamaro P, Meazza C, Alaggio R, Ninfo V, Carli M, Italian Cooperative Group.
    Cancer; 2003 May 15; 97(10):2597-604. PubMed ID: 12733159
    [Abstract] [Full Text] [Related]

  • 36. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H.
    Ann Surg Oncol; 2008 Sep 15; 15(9):2426-32. PubMed ID: 18521686
    [Abstract] [Full Text] [Related]

  • 37. Rhabdomyosarcoma in children--a ten year review.
    Bradford WB, Jose BO, Butler D, Lindberg RD, Paris K, Spanos WJ, Patel CC, Bertolone SJ.
    J Ky Med Assoc; 1998 Oct 15; 96(10):399-402. PubMed ID: 9803061
    [Abstract] [Full Text] [Related]

  • 38. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma.
    Dantonello TM, Int-Veen C, Winkler P, Leuschner I, Schuck A, Schmidt BF, Lochbuehler H, Kirsch S, Hallmen E, Veit-Friedrich I, Bielack SS, Niggli F, Kazanowska B, Ladenstein R, Wiebe T, Klingebiel T, Treuner J, Koscielniak E.
    J Clin Oncol; 2008 Jan 20; 26(3):406-13. PubMed ID: 18202417
    [Abstract] [Full Text] [Related]

  • 39. Myogenin and desmin immunohistochemistry in the assessment of post-chemotherapy genitourinary embryonal rhabdomyosarcoma: prognostic and management implications.
    Godbole P, Outram A, Wilcox DT, Duffy PG, Sebire NJ.
    J Urol; 2006 Oct 20; 176(4 Pt 2):1751-4. PubMed ID: 16945640
    [Abstract] [Full Text] [Related]

  • 40. Local tumor control in rhabdomyosarcoma following low-dose irradiation: comparison of group II and select group III patients.
    Regine WF, Fontanesi J, Kumar P, Ayers D, Bowman LC, Pappo AS, Coffey DH, Avery L, Rao BN, Kun LE.
    Int J Radiat Oncol Biol Phys; 1995 Feb 01; 31(3):485-91. PubMed ID: 7852110
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.